LE WE PMID CA
Biologicals (Pharmacology)4734Biologicals (Pharmakologie)

Biologicals (Pharmacology)

Radiopharmacology

TNF alpha

2009  
1
Infectious complications associated with monoclonal antibodies and related small molecules.
[19366915] Clin Microbiol Rev 22(2): 274-90, Table of Contents (2009)
2009  
2
Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy.
[19861045] Emerg Infect Dis 15(10): 1556-61 (2009)
2009  
3
Leishmaniasis, autoimmune rheumatic disease, and anti-tumor necrosis factor therapy, Europe.
[19523302] Emerg Infect Dis 15(6): 956-9 (2009)
2006  
4
Adverse side-effects to biological agents.
[16867042] Allergy 61(8): 912-20 (2006)
2006  
5
A medical conundrum: onset of psoriasis in patients receiving anti-tumour necrosis factor agents.
[17105851] Ann Rheum Dis 65(12): 1541-4 (2006)
2008  
6
Review article: minimizing tuberculosis during anti-tumour necrosis factor-alpha treatment of inflammatory bowel disease.
[17944997] Aliment Pharmacol Ther 27(1): 19-30 (2008)
2003  
7
Infusion reactions to infliximab in children and adolescents: frequency, outcome and a predictive model.
[12492735] Aliment Pharmacol Ther 17(1): 75-84 (2003)
2009  
8
Review article: anti TNF-alpha induced psoriasis in patients with inflammatory bowel disease.
[19210297] Aliment Pharmacol Ther 29(9): 921-7 (2009)
2008  
9
The impact of infliximab infusion reactions on long-term outcomes in patients with Crohn's disease.
[18485127] Aliment Pharmacol Ther 28(2): 221-7 (2008)
2009  
10
Skin toxicities associated with epidermal growth factor receptor inhibitors.
[19452131] Target Oncol 4(2): 107-19 (2009)
2009  
11
Renal toxicity of targeted therapies.
[19421832] Target Oncol 4(2): 121-33 (2009)
2009  
12
Serosal inflammation (pleural and pericardial effusions) related to tyrosine kinase inhibitors.
[19381453] Target Oncol 4(2): 99-105 (2009)
2009  
13
Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors.
[19373440] Target Oncol 4(2): 67-76 (2009)
2008  
14
Hematopoietic growth factors: ESMO recommendations for the applications.
[18456747] Ann Oncol 19 Suppl 2(-): ii116-8 (2008)
2007  
15
The clinical use of antibodies in haematological malignancies.
[17631596] Ann Oncol 18 Suppl 9(-): ix51-7 (2007)
2005  
16
Clinical signs, pathophysiology and management of skin toxicity during therapy with epidermal growth factor receptor inhibitors.
[16012181] Ann Oncol 16(9): 1425-33 (2005)
2007  
17
Mechanisms of adverse effects of anti-VEGF therapy for cancer.
[17519900] Br J Cancer 96(12): 1788-95 (2007)
2007  
18
Infectious complications of monoclonal antibodies used in cancer therapy: a systematic review of the evidence from randomized controlled trials.
[17429839] Cancer 109(11): 2182-9 (2007)
2003  
19
Molecular therapeutics: is one promiscuous drug against multiple targets better than combinations of molecule-specific drugs?
[12684387] Clin Cancer Res 9(4): 1231-2 (2003)
2008  
20
Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib.
[18779536] Oncologist 13(9): 1001-11 (2008)
2008  
21
Managing premedications and the risk for reactions to infusional monoclonal antibody therapy.
[18586928] Oncologist 13(6): 725-32 (2008)
2007  
22
Review: side effects of approved molecular targeted therapies in solid cancers.
[18165622] Oncologist 12(12): 1443-55 (2007)
2007  
23
Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007.
[17934088] Ann Rheum Dis 66 Suppl 3(-): iii2-22 (2007)
2005  
24
Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005.
[16239380] Ann Rheum Dis 64 Suppl 4(-): iv2-14 (2005)
2011  
25
Promising new treatments for rheumatoid arthritis - the kinase inhibitors.
[22035435] Bull NYU Hosp Jt Dis 69(3): 233-7 (2011)
2009  
26
Lupus-like syndrome attributable to anti-tumor necrosis factor alpha therapy in 14 patients during an 8-year period at Mayo Clinic.
[19880688] Mayo Clin Proc 84(11): 979-84 (2009)
2008  
27
Development of sarcoidosis during etanercept therapy.
[18520114] Intern Med 47(11): 1021-5 (2008)
2011  
28
Cutaneous side-effects of EGFR inhibitors and their management.
[21293833] Skin Therapy Lett 16(1): 1-3 (2011)
2007  
29
Cutaneous reactions to anticancer agents targeting the epidermal growth factor receptor: a dermatology-oncology perspective.
[17762902] Skin Therapy Lett 12(6): 1-5 (2007)
2010  
30
How tumour necrosis factor blockers interfere with tuberculosis immunity.
[20491796] Clin Exp Immunol 161(1): 1-9 (2010)
2011  
31
Molecular target therapy in hematological malignancy: front-runners and prototypes of small molecule and antibody therapy.
[21113055] Jpn J Clin Oncol 41(2): 157-64 (2011)
2009  
32
Long-term efficacy of biologics in dermatology.
[19222514] Dermatol Ther 22(1): 22-33 (2009)

Downloaded from http://www.kidney.de - The Database of Free Medical Reviews - The Metatextbook of Medicine - Ossip Groth

All Medline data shown were primarily retrieved from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.



  • Biologicals (Pharmakologie)

  • The BDOM Bibliographic Dictionary of Medicine is a curated collection of free medical articles tagged to concepts.
    Contents until 2011 are reviews from PubMed, contents flagged 'PMC' are regular articles from PubMed Central.
    Search BDOM
    Nephrology Collection
    Radiology Locator

    PubMedCentral monthly collection of free medical articles by major subject

    The framed wikipedia articles are from en.wikipedia.org and they are the actual versions; the first is from Nephropedia